
    
      Vvax001 is a therapeutic cancer vaccine consisting of a replication-incompetent Semliki
      Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three
      consecutive doses, with an interval of 3 weeks.
    
  